Login to Your Account



Pharma: Other News To Note


Thursday, May 9, 2013

• Merck & Co. Inc., of Whitehouse Station, N.J., said the biologics license application (BLA) for its investigational ragweed pollen (Ambrosia artemisiifolia) sublingual allergy immunotherapy tablet was accepted for review by the FDA.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription